Tetravalent DNA vaccine product as a vaccine candidate against dengue.
Dengue is the most important arbovirus worldwide and is the virus that causes dengue fever and the more severe dengue hemorrhagic fever. There are four serotypes of dengue with each possessing the ability to cause disease. Developing a preventive vaccine is the most efficient and effective way to prevent these diseases, and because immunity to one serotype does not protect against the other serotypes, a vaccine must provide tetravalent protection. We used DNA immunization as a platform to develop a tetravalent vaccine. In this chapter, we describe the laboratory, regulatory, and clinical methodology for evaluating a candidate tetravalent vaccine in a Phase 1 clinical trial.
Infectious Disease Directorate, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD, 20910, USA, kevin.porter@med.navy.mil.
Kevin R
KR
Porter
Nimfa
N
Teneza-Mora
Kanakatte
K
Raviprakash
D017321:Clinical Trials, Phase I as Topic; D003715:Dengue / Q000517:prevention & control*; D006801:Humans; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D019444:Vaccines, DNA; D014765:Viral Vaccines